SCHEMBL30748770

SCHEMBL30748770

CC1(NC#N)CCCCC1

nearest known ligand 0.35

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.35
ALDH1A1 P00352 1/20 0.35
PDE4A P27815 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11879360 0.86
SCHEMBL9713932 0.74 DPP4 (0.32) DPP4
SCHEMBL4925574 0.74 DPP4 (0.32) DPP4
SCHEMBL25784560 0.72 USP2 (0.33)
SCHEMBL9713830 0.70
SCHEMBL5703365 0.67 HDAC3 (0.31)
SCHEMBL40483 0.67 HDAC3 (0.31)
SCHEMBL284643 0.67 HDAC3 (0.31)
SCHEMBL23188550 0.65
SCHEMBL18900552 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT DPP4 914/4885ALDH1A1 256/4885PDE4A 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.